ERAS
Price
$14.39
Change
+$0.36 (+2.56%)
Updated
Oct 23, 04:59 PM (EDT)
Capitalization
4.91B
19 days until earnings call
Intraday BUY SELL Signals
MLTX
Price
$11.85
Change
-$0.49 (-3.97%)
Updated
Oct 23, 04:59 PM (EDT)
Capitalization
1.05B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs MLTX

ERAS vs MLTX Comparison Chart in %
View a ticker or compare two or three
VS
ERAS vs. MLTX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and MLTX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ERAS with price predictions
Oct 22, 2026

ERAS's Indicator enters downward trend

The Aroon Indicator for ERAS entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 191 of the 212 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ERAS as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ERAS's RSI Oscillator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where ERAS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on October 20, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 46 of 56 cases over the following month. The odds of a continued upward trend are 82%.

Following a +9.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.570) is normal, around the industry mean (2.973). P/E Ratio (-14.779) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MLTX with price predictions
Oct 22, 2026

MLTX in +19.57% Uptrend, advancing for three consecutive days on October 22, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Indicator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 68 cases where MLTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on MLTX as a result. In 80 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 43 of 53 cases over the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The 50-day moving average for MLTX moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

MLTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MLTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.453) is normal, around the industry mean (2.973). P/E Ratio (-3.214) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
MLTX: Fundamental Ratings
MLTX
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASMLTX
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ERAS: $14.04 vs. MLTX: $12.34)
Brand notoriety: ERAS and MLTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 43% vs. MLTX: 329%
Market capitalization -- ERAS: $4.91B vs. MLTX: $1.05B
ERAS [@Biotechnology] is valued at $4.91B. MLTX’s [@Biotechnology] market capitalization is $1.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 2 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 2 green, 3 red.
  • MLTX’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than MLTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while MLTX’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 3 bearish.
  • MLTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than MLTX.

Price Growth

ERAS (@Biotechnology) experienced а -5.58% price change this week, while MLTX (@Biotechnology) price change was +20.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was -16.27%, and the average quarterly price growth was -16.72%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 11, 2026.

MLTX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ERAS
Daily Signal:
Gain/Loss:
MLTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with SNGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then SNGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-3.11%
SNGX - ERAS
54%
Loosely correlated
+0.30%
REPL - ERAS
42%
Loosely correlated
+2.30%
AMLX - ERAS
39%
Loosely correlated
-1.58%
GLUE - ERAS
36%
Loosely correlated
-0.98%
RZLT - ERAS
36%
Loosely correlated
+4.32%
More

MLTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLTX
1D Price
Change %
MLTX100%
+15.87%
KALA - MLTX
82%
Closely correlated
-2.78%
CGON - MLTX
50%
Loosely correlated
+0.48%
XENE - MLTX
44%
Loosely correlated
+1.53%
ELVN - MLTX
44%
Loosely correlated
+0.26%
AURA - MLTX
43%
Loosely correlated
N/A
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VXX18.481.09
+6.27%
iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX)
RAAA25.070.01
+0.02%
Reckoner Yield Enhanced AAA CLO ETF (RAAA)
BGX10.48-0.01
-0.10%
Blackstone Long-Short Credit Income Fund
IVOO123.19-1.03
-0.83%
Vanguard S&P Mid-Cap 400 ETF (IVOO)
DWSH5.44-0.18
-3.22%
AdvisorShares Dorsey Wright Short ETF (DWSH)